Radius Raises $91 Million, Moves Toward Public Listing
This article was originally published in Start Up
Just two years ago Radius Health Inc. had a straightforward partnering strategy for its osteoporosis drug, BA058. Now that a key partner has opted not to exercise its option on the compound, Radius has instead raised a massive new round of funding that allows the company to keep full ownership of the compound. In addition, the crafting of a creative exit strategy alongside the financing paves a path to liquidity for its shareholders.
You may also be interested in...
With its IPO withdrawn, osteoporosis drug developer Radius Therapeutics is likely to seek funding from institutional backers. The company has just enough cash to last it through the first quarter, with big costs for a Phase III trial in the works.
Financings Of The Fortnight: Crossover Investors Key To Intarcia’s Massive $210 Million Series C Round
Plus news on recent financings by Visterra, AbbVie, Pearl Therapeutics and Auspex.
The U.K.’s largest charitable foundation for biomedical research is the sole investor in a new fund that will target start-ups as well as later-stage growth opportunities across the health care spectrum.